S. Breiteneder-geleff et al., Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries - Podoplanin as a specific marker for lymphatic endothelium, AM J PATH, 154(2), 1999, pp. 385-394
Citations number
29
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Angiosarcomas apparently derive from blood vessel endothelial cells; howeve
r, occasionally their histological features suggest mixed origin from blood
and lymphatic endothelia. In the absence of specific positive markers for
lymphatic endothelia the precise distinction between these components has n
ot been possible, Here we provide evidence by light and electron microscopi
c immunohistochemistry that podoplanin, a similar to 38-kd membrane glycopr
otein of podocytes, is specifically expressed in the endothelium of lymphat
ic capillaries, but not in the blood vasculature, In normal skin and kidney
, podoplanin colocalized with vascular endothelial growth factor receptor-3
, the only other lymphatic marker presently available. Complementary immuno
staining of blood vessels was obtained with established endothelial markers
(CD31, CD34, factor VIII-related antigen, and Ulex europaeus I lectin) as
well as podocalyxin, another podocytic protein that is also localized in en
dothelia of blood vessels. Podoplanin specifically immunolabeled endothelia
of benign tumorous lesions of undisputed lymphatic origin (lymphangiomas,
hygromas) and was detected there as a 38-kd protein by immunoblotting, As p
aradigms of malignant vascular tumors, poorly differentiated (G3) common an
giosarcomas (n = 8), epitheloid angiosarcomas (n = 3), and intestinal Kapos
i's sarcomas (n = 5) were examined for their podoplanin content in relation
to conventional endothelial markers. The relative number of tumor cells ex
pressing podoplanin was estimated and, although the number of cases in this
preliminary study was limited to 16, an apparent spectrum of podoplanin ex
pression emerged that can be divided into a low-expression group in which 0
-10% of tumor cells contained podoplanin, a moderate-expression group with
30-60% and a high-expression group with 70-100%. Ten of eleven angiosarcoma
s and all Kaposi's sarcomas showed mixed expression of both lymphatic and b
lood vascular endothelial phenotypes. By double labeling, most podoplanin-p
ositive tumor cells coexpressed endothelial markers of blood vessels, where
as few tumor cells were positive for individual markers only, From these re
sults we conclude that (1) podoplanin is a selective marker of lymphatic en
dothelium; (2) G3 angiosarcomas display a quantitative spectrum of podoplan
in-expressing tumor cells; (3) in most angiosarcomas, a varying subset of t
umor cells coexpresses podoplanin and endothelial markers of blood vessels;
and (4) all endothelial cells of Kaposi's sarcomas expressed the lymphatic
marker podoplanin.